查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011595

藥物安全檢測市場：按類型、產品生命週期、給藥方式、流程、治療領域和最終用戶分類－2026-2032年全球市場預測

Pharmacovigilance Market by Type, Product Life Cycle, Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物安全檢測市場價值將達到 118.4 億美元，到 2026 年將成長至 137.1 億美元，到 2032 年將達到 341.7 億美元，年複合成長率為 16.34%。

主要市場統計數據
基準年 2025 118.4億美元
預計年份：2026年 137.1億美元
預測年份 2032 341.7億美元
複合年成長率 (%) 16.34%

對現代藥物安全檢測面臨的關鍵挑戰進行了簡要概述，反映了數據的複雜性、不斷變化的法規以及組織在安全管治的準備。

藥物安全檢測處於病人安全、監管和商業性永續性的交匯點。隨著治療方法創新加速發展，真實世界數據（REW）的重要性日益凸顯，安全監測模式必須適應更複雜的資料來源、更短的研發週期和更嚴格的監管審查。本文總結了重塑該領域的關鍵因素，涵蓋資料架構和自動化、人才模式以及跨職能管治等各個面向。

探索正在重新定義藥物安全檢測實踐的關鍵結構和技術變革，包括人工智慧、真實世界證據和現代監管期望。

藥物安全檢測領域正經歷著由技術創新、監管現代化和策略採購所驅動的變革。人工智慧 (AI) 和機器學習能夠透過跨資料集的模式識別，及早發現安全訊號；而自然語言處理則能夠更有效地從醫療記錄和社交媒體等自由文字來源中提取相關資訊。這些能力與日趨成熟的真實世界資料生態系統相輔相成，使安全團隊能夠將縱向病患資訊添加到傳統的臨床試驗資料中。

對 2025 年費用修訂措施如何重組藥物安全檢測業務的供應鏈選擇、外包策略和成本管治進行全面評估。

2025年關稅上調引發了整個藥物安全檢測的一系列營運和戰略應對措施，影響了供應鏈、服務採購和成本結構。進口關稅的提高推高了某些醫療設備及相關硬體的成本，促使一些機構重新評估其資本累積時機，並考慮在地採購以降低跨境課稅風險。這些採購壓力間接影響藥物安全檢測，尤其是在監測工作流程中包含器械主導診斷和第三方安全硬體的情況下。

詳細的細分分析揭示了安全調查方法、生命週期階段、交付模式、流程架構、治療領域和最終用戶概況如何影響藥物安全檢測的優先事項。

關鍵細分洞察揭示了基於安全資料收集方法、臨床開發階段、交付模式、流程架構、治療領域和最終用戶類型的不同策略重點。考慮到這些類型，每種方法——隊列心臟事件記錄器、電子健康記錄挖掘、增強型不良反應報告、自願報告和定向自願報告——都對數據品質、延遲和檢驗提出了不同的要求。隊列心臟事件記錄器和電子健康記錄挖掘需要強大的縱向數據整合和高級分析，而自願報告則強調快速資料擷取和標準化編碼工作流程。

區域評估監管、資料基礎設施和服務能力方面的區域差異如何促使製定統一的全球標準和在地化的實施策略。

區域趨勢對跨轄區營運設計、監管策略和資源分配決策有重大影響。在美洲，傳統法規結構正與真實世界數據 (REW) 的快速應用以及對上市後監測的嚴格要求相輔相成，從而推動了對可擴展分析平台和強大的本地藥物安全檢測專業知識的需求。在該地區，能夠同時應對集中式監管問詢和分散式醫療保健資料來源的整合式端到端解決方案更受青睞。

技術深度、治療領域的專業知識和靈活的交付模式決定了供應商的長期相關性：這是對競爭定位的評估觀點。

在藥物安全檢測領域運作的公司，其競爭基礎在於技術能力、領域專業知識以及提供靈活交付模式的能力，以滿足客戶特定的監管和營運需求。市場領先的機構正在投資模組化分析平台，這些平台支援自動化訊號檢測和可配置的工作流程編配，從而能夠快速適應申辦方的偏好和檢查要求。這些投資通常與有針對性的招募和夥伴關係策略相結合，以確保獲得能夠評估細微因果關係的治療領域專家和經驗豐富的安全醫師。

為領導者提供實用、策略性的方法，將高階分析、混合採購、管治和人才發展整合到強大的藥物安全檢測計畫中。

產業領導者應優先考慮重點策略舉措，以在維持營運韌性的同時提升安全性。首先，應迅速將進階分析和自然語言處理技術整合到核心監測活動中，以減輕人工負擔、提高訊號靈敏度並縮短洞察時間。同時，應建立清晰的檢驗和管治框架，以確保演算法輸出符合監管和臨床標準。

嚴謹的多面向調查方法，結合二手調查、專家訪談、三角檢驗和情境分析，確保了基於證據的實用見解。

本分析的調查方法結合了多層次的證據收集、檢驗和整合，以確保其嚴謹性和實用性。首先，我們進行了一項全面的二手資料調查，涵蓋監管指南、同行評審文獻和公開的安全通告，以掌握當前的標準、近期政策變化和方法創新。在此基礎上，我們開展了有針對性的一手調查，包括對安全官員、監管專家、臨床開發主管和供應商進行結構化訪談，以了解實際運作和不斷變化的優先事項。

綜合分析得出的結論強調了製定綜合資料策略、適應性管治和彈性資料收集的必要性。

總之，在分析技術進步、監管預期變化以及商業性和地緣政治壓力轉變的推動下，藥物安全檢測正在經歷重大變革。那些積極擁抱資料整合、現代化管治和混合交付模式的機構，將更有能力及早發現安全訊號，更果斷地做出反應，並維護監管機構和公眾的信任。供應鏈和關稅趨勢的累積影響凸顯了合約韌性和地理分散化在維持專案連續性的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：藥物安全檢測市場：按類型分類

  • 佇列心臟事件記錄器
  • 電子健康記錄（EHR）挖掘
  • 增強型ADR報告
  • 自願報告
  • 有針對性的自願報告

第9章 依產品生命週期分類的藥物安全檢測市場

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段
  • 臨床前

第10章：藥物安全檢測市場：以交付方式分類

  • 內部回應
  • 外包

第11章藥物安全檢測市場流程分析

  • 案例資料管理
    • 案例數據分析
    • 病例記錄
    • 醫學審查和報告
  • 風險管理系統
    • 風險評估系統
    • 風險緩解系統
  • 訊號檢測
    • 不利事件分析
    • 不利事件記錄
    • 不利事件的審查和報告

第12章藥物安全檢測市場：依治療領域分類

  • 循環系統
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 呼吸系統

第13章藥物安全檢測市場：依最終用戶分類

  • 生技公司
  • 醫療設備製造商
  • 製藥公司

第14章藥物安全檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章藥物安全檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章藥物安全檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國藥物安全檢測市場

第18章：中國藥物安全檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi SA
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited
Product Code: MRR-43676CF420A3

The Pharmacovigilance Market was valued at USD 11.84 billion in 2025 and is projected to grow to USD 13.71 billion in 2026, with a CAGR of 16.34%, reaching USD 34.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.84 billion
Estimated Year [2026] USD 13.71 billion
Forecast Year [2032] USD 34.17 billion
CAGR (%) 16.34%

A succinct orientation to contemporary pharmacovigilance imperatives reflecting data complexities, regulatory evolution, and organizational readiness for safety governance

Pharmacovigilance sits at the intersection of patient safety, regulatory stewardship, and commercial sustainability. As therapeutic innovation accelerates and real-world evidence gains prominence, safety monitoring paradigms must adapt to more complex data sources, accelerated development timelines, and heightened regulatory scrutiny. This introduction synthesizes the core drivers that are reshaping the discipline, from data architecture and automation to workforce models and cross-functional governance.

Contemporary safety functions are increasingly required to balance rapid signal detection with methodical risk evaluation, while enabling product teams to make timely, evidence-informed decisions. The integration of electronic health records, registries, and patient-reported outcomes is expanding both the volume and heterogeneity of safety inputs, necessitating robust data curation and validation practices. Meanwhile, regulators are signaling expectations for stronger post-market surveillance and risk minimization planning, prompting organizations to re-evaluate roles, workflows, and technology investments.

Transitioning from manual, document-centric approaches to modular, analytics-driven systems is no longer optional for organizations aiming to maintain compliance and competitive differentiation. This introduction establishes the foundational context for the subsequent sections, emphasizing that pragmatic governance, scalable data strategy, and skilled multidisciplinary teams are essential to ensure safety objectives are met across product lifecycles and global markets.

An exploration of the major structural and technological shifts redefining pharmacovigilance operations including AI, real-world evidence, and modern regulatory expectations

The pharmacovigilance landscape is experiencing transformative shifts driven by technological innovation, regulatory modernization, and strategic sourcing. Artificial intelligence and machine learning are enabling earlier identification of safety signals through pattern recognition across disparate datasets, while natural language processing improves the extraction of relevant information from free-text sources such as medical notes and social media. These capabilities are complemented by maturing real-world data ecosystems that allow safety teams to augment traditional clinical trial evidence with longitudinal patient information.

Concurrently, regulators are evolving expectations for transparency, proactive risk management, and the incorporation of real-world evidence into safety decision-making. This regulatory momentum is prompting organizations to move beyond compliance checklists and toward continuous evidence generation frameworks that emphasize lifecycle safety. Operationally, many safety organizations are adopting hybrid delivery models that combine in-house expertise for strategic oversight with outsourced capabilities for scale and specialized analytics, enabling rapid ramp-up during peak activities.

Culturally, cross-functional integration of pharmacovigilance with clinical development, regulatory affairs, and commercial teams is becoming essential to accelerate time-to-decision and to design pragmatic risk mitigation strategies. As a result, leaders are investing in change management, upskilling, and formalized governance to ensure that new tools and data sources are leveraged responsibly and effectively. Together, these shifts redefine what it means to deliver high-quality patient safety in an increasingly dynamic therapeutic and regulatory environment.

A comprehensive assessment of how 2025 tariff measures have reshaped supply chain choices, outsourcing strategies, and cost governance across pharmacovigilance operations

The introduction of enhanced tariffs in 2025 has produced a cascade of operational and strategic responses across the pharmacovigilance ecosystem, affecting supply chains, service procurement, and cost structures. Increased duties on imported goods have elevated the cost base for certain medical devices and supporting hardware, prompting some organizations to re-evaluate capital procurement timing and to consider localized sourcing to reduce exposure to cross-border levies. These procurement pressures have indirect implications for pharmacovigilance, especially where instrument-driven diagnostics or third-party safety hardware are part of surveillance workflows.

In addition, tariff-driven cost inflation has influenced outsourcing decisions. Some sponsors have shifted to more geographically balanced outsourcing arrangements, favoring service providers with delivery centers in regions with lower tariff exposure or with established nearshore capabilities. This redistribution aims to preserve budget flexibility for data analytics investments while maintaining capacity for case processing, medical review, and query management. At the same time, vendor contracts are being renegotiated to include clauses that address tariff volatility, cost pass-through, and contingency staffing to preserve continuity of safety operations.

Regulatory compliance budgets have also felt downstream effects. Organizations are prioritizing investments that directly enhance signal detection and regulatory responsiveness, given the operational constraints imposed by tariff-related cost pressures. Overall, the cumulative impact of the 2025 tariff changes has accelerated strategic localization of supply and delivery, strengthened contractual risk management, and intensified the focus on efficiency improvements across pharmacovigilance processes to preserve program resilience and patient safety outcomes.

In-depth segmentation analysis revealing how safety methodology, lifecycle stage, delivery models, process architecture, therapeutic focus, and end-user profiles shape pharmacovigilance priorities

Key segmentation insights reveal differentiated strategic priorities across methods of safety capture, clinical development stages, delivery models, process architecture, therapeutic focus, and end-user types. When considering Type, approaches such as Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting each impose distinct data quality, latency, and validation requirements; Cohort Event Monitoring and EHR Mining demand strong longitudinal data linkage and advanced analytics, while Spontaneous Reporting emphasizes rapid intake and standardized coding workflows.

Considering Product Life Cycle, requirements vary significantly across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical stages. Early phases prioritize safety signal characterization and close medical oversight, whereas Phase IV activities emphasize long-term risk minimization and integration of post-market surveillance data. Delivery Mode also dictates capability design: In-house models support strategic oversight, knowledge retention, and direct regulatory interface, while Outsourced models provide scalability, specialized expertise, and cost flexibility during peak activity windows.

Process Flow segmentation highlights distinct operational foci across Case Data Management, Risk Management System, and Signal Detection. Case Data Management encompasses case data analysis, case logging, and medical reviewing and reporting, requiring robust case-tracking, quality control, and therapeutic expertise. The Risk Management System incorporates risk evaluation system and risk mitigation system capabilities that support lifecycle risk assessment and the implementation of targeted interventions. Signal Detection functions involve adverse event analysis, adverse event logging, and adverse event review and reporting, relying on statistical monitoring, data harmonization, and multidisciplinary adjudication.

Therapeutic Area segmentation-spanning cardiovascular, infectious diseases, neurology, oncology, and respiratory-shapes the expected event typologies, monitoring cadence, and specialist expertise required for accurate causality assessment. End-user distinctions among biotechnology companies, medical device manufacturers, and pharmaceuticals influence contracting models, acceptable risk-tolerance thresholds, and the degree of regulatory engagement expected, with each end-user type balancing speed to insight against the need for rigorous medical and regulatory evidence.

A regional appraisal of how jurisdictional variation in regulation, data infrastructure, and service capabilities demands integrated global standards with localized execution strategies

Regional dynamics materially influence operational design, regulatory strategy, and resourcing decisions across jurisdictions. In the Americas, legacy regulatory frameworks are being augmented by accelerated adoption of real-world evidence and robust post-market surveillance expectations, driving demand for scalable analytics platforms and strong local pharmacovigilance expertise. This region favors integrated end-to-end solutions that can respond to both centralized regulatory inquiries and decentralized healthcare data sources.

Across Europe, Middle East & Africa, heterogeneity in regulatory maturities requires adaptable engagement strategies. The European regulatory environment places emphasis on transparency, data protection, and cross-border pharmacovigilance cooperation, while markets in the Middle East and Africa present variable infrastructure and data availability that often necessitate hybrid approaches combining centralized analytics with targeted local studies. Consequently, organizations operating in this broad region must balance pan-regional standardization with localized execution flexibility.

The Asia-Pacific landscape is characterized by rapid adoption of digital health technologies, growing clinical trial activity, and an expanding pool of specialized service providers. Diverse regulatory regimes in the region create opportunities for nearshore delivery models and regional hubs that provide cost efficiency and time zone alignment for sponsors. Together, these regional insights suggest that successful pharmacovigilance strategies require a mosaic approach: harmonized global standards layered with regionally tailored processes and partnerships that reflect local regulatory expectations, data ecosystems, and operational readiness.

An evaluative perspective on competitive positioning where technological depth, therapeutic expertise, and flexible delivery models determine long-term vendor relevance

Companies operating in the pharmacovigilance space are competing on the basis of technological capability, domain expertise, and the ability to deliver flexible delivery models that meet client-specific regulatory and operational needs. Market-leading organizations are investing in modular analytics platforms that support both automated signal detection and configurable workflow orchestration, enabling rapid adaptation to sponsor preferences and inspection requirements. These investments are frequently paired with focused recruitment or partnership strategies to secure therapeutic-area specialists and experienced safety physicians capable of nuanced causality assessment.

Strategic partnerships between technology providers, contract safety organizations, and data custodians are increasingly common, enabling bundled offerings that combine data access, analytics, and case processing at scale. At the same time, nimble boutique providers differentiate through deep therapeutic expertise or specialized services such as intensified ADR reporting programs, targeted spontaneous reporting frameworks, and bespoke risk evaluation systems. Buyers are scrutinizing vendor governance structures, evidence of regulatory inspection readiness, and demonstrable outcomes such as cycle-time reductions and improvements in signal-to-noise ratios.

Competitive positioning is also influenced by geographic delivery footprint and the ability to provide hybrid in-house and outsourced models that align with client risk tolerances. Companies that can demonstrate robust quality systems, transparent pricing models, and agile implementation methodologies are most likely to secure long-term partnerships as sponsors prioritize reliability, scalability, and the capacity to integrate emerging data streams into established pharmacovigilance processes.

Actionable strategic initiatives for leaders to embed advanced analytics, hybrid sourcing, governance, and workforce development into robust pharmacovigilance programs

Industry leaders should prioritize a focused set of strategic initiatives to strengthen safety outcomes while maintaining operational resilience. First, accelerate integration of advanced analytics and natural language processing into core surveillance activities to reduce manual effort, increase signal sensitivity, and shorten time-to-insight. Simultaneously, establish clear validation and governance frameworks to ensure algorithmic outputs meet regulatory and clinical standards.

Second, adopt a hybrid sourcing strategy that combines in-house leadership for critical judgment functions with outsourced scale for routine processing and specialized analytics. This approach preserves institutional knowledge while enabling rapid capacity management during clinical accelerations or post-market demands. Third, cultivate cross-functional governance that embeds pharmacovigilance metrics into development decision-making, regulatory planning, and commercial strategy to ensure safety considerations are factored into lifecycle choices.

Fourth, invest in workforce development to upskill safety professionals in data science, regulatory intelligence, and evidence synthesis, thereby enhancing the team's ability to interpret complex signals and to communicate decisions to stakeholders. Fifth, design contractual safeguards with vendors to manage geopolitical and tariff-related risks, including clauses for cost adjustment, contingency staffing, and data sovereignty. By implementing these focused actions, organizations can enhance their ability to detect and mitigate risks, preserve compliance, and sustain trust among providers, payers, and patients.

A rigorous multi-method research approach combining secondary review, expert interviews, triangulation, and scenario analysis to ensure evidence-based and pragmatic insights

The research methodology underpinning this analysis combined a layered approach to evidence gathering, validation, and synthesis to ensure rigor and practical relevance. The process began with comprehensive secondary research encompassing regulatory guidance, peer-reviewed literature, and public domain safety communications to map current standards, recent policy shifts, and methodological innovations. This foundation informed targeted primary research involving structured interviews with safety leaders, regulatory specialists, clinical development executives, and vendors to capture operational realities and evolving priorities.

Data triangulation techniques were applied to reconcile divergent perspectives, with scenario-based analyses used to stress-test strategic responses against variables such as tariff shifts, regional regulatory changes, and rapid adoption of new data sources. Quality control included methodological audits, cross-validation of key assertions with independent domain experts, and iterative review cycles to ensure factual accuracy and practical applicability. Wherever analytic models were used to illustrate process implications, they were accompanied by sensitivity examinations to highlight key assumptions and to delineate areas requiring further empirical validation.

This multi-method approach was designed to deliver findings that are both evidence-based and pragmatically oriented, supporting leaders in translating strategic insight into operational decisions while accounting for the inherent complexity of global pharmacovigilance ecosystems.

A concluding synthesis emphasizing the necessity of integrated data strategies, adaptive governance, and resilient sourcing to secure sustained pharmacovigilance excellence

In conclusion, pharmacovigilance is undergoing substantive transformation driven by advances in analytics, shifts in regulatory expectations, and evolving commercial and geopolitical pressures. Organizations that embrace data integration, governance modernization, and hybrid delivery models will be better positioned to detect safety signals earlier, to respond more decisively, and to maintain regulatory and public trust. The cumulative effects of supply chain and tariff dynamics underscore the importance of contractual resilience and geographic diversification in sustaining program continuity.

The segmentation and regional analyses highlight that there is no single operational model that fits all contexts; instead, successful programs align methodological choices with lifecycle stage, therapeutic complexity, and end-user priorities. Competitive advantage will accrue to organizations that combine technological investments with domain expertise and agile operating models. Ultimately, pharmacovigilance must be treated as a strategic capability that protects patients while enabling therapeutic innovation, and the pathway to that capability requires deliberate investments in people, process, and technology.

Leaders should view the recommendations and insights in this report as a practical blueprint for action: prioritize analytics and governance, refine sourcing strategies, and invest in the workforce to sustain high-quality safety outcomes in a rapidly changing environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmacovigilance Market, by Type

  • 8.1. Cohort Event Monitoring
  • 8.2. EHR Mining
  • 8.3. Intensified ADR Reporting
  • 8.4. Spontaneous Reporting
  • 8.5. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by Product Life Cycle

  • 9.1. Phase I
  • 9.2. Phase II
  • 9.3. Phase III
  • 9.4. Phase IV
  • 9.5. Pre-clinical

10. Pharmacovigilance Market, by Delivery Mode

  • 10.1. In-house
  • 10.2. Outsourced

11. Pharmacovigilance Market, by Process Flow

  • 11.1. Case Data Management
    • 11.1.1. Case Data Analysis
    • 11.1.2. Case Logging
    • 11.1.3. Medical Reviewing & Reporting
  • 11.2. Risk Management System
    • 11.2.1. Risk Evaluation System
    • 11.2.2. Risk Mitigation System
  • 11.3. Signal Detection
    • 11.3.1. Adverse Event Analysis
    • 11.3.2. Adverse Event Logging
    • 11.3.3. Adverse Event Review & Reporting

12. Pharmacovigilance Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. Infectious Diseases
  • 12.3. Neurology
  • 12.4. Oncology
  • 12.5. Respiratory

13. Pharmacovigilance Market, by End-user

  • 13.1. Biotechnology Companies
  • 13.2. Medical Device Manufacturers
  • 13.3. Pharmaceuticals

14. Pharmacovigilance Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Pharmacovigilance Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Pharmacovigilance Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Pharmacovigilance Market

18. China Pharmacovigilance Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accenture, PLC
  • 19.6. Bristol-Myers Squibb Company
  • 19.7. Capgemini SE
  • 19.8. ClinChoice
  • 19.9. F. Hoffmann-La Roche AG
  • 19.10. GlaxoSmithKline PLC
  • 19.11. HCL Technologies Limited
  • 19.12. ICON PLC
  • 19.13. Infosys Limited
  • 19.14. International Business Machines Corporation
  • 19.15. IQVIA Inc.
  • 19.16. ITclinical
  • 19.17. Laboratory Corporation of America Holdings
  • 19.18. Linical Co., Ltd.
  • 19.19. Novartis AG
  • 19.20. Oracle Corporation
  • 19.21. Parexel International
  • 19.22. Pfizer Inc.
  • 19.23. Quanticate International limited
  • 19.24. Sanofi S.A.
  • 19.25. Syneos Health
  • 19.26. TAKE Solutions Limited
  • 19.27. TATA Consultancy Services Limited
  • 19.28. Wipro Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 201. GCC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 202. GCC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 231. G7 PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 232. G7 PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 233. G7 PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. G7 PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 241. NATO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 242. NATO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 243. NATO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 245. NATO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)